WASHINGTON, July 14 — A June 2024 clinical trial for the investigational CAR-T therapy CTX-112 recorded cytokine release syndrome in 45 percent of patients, with severe cases in 8 percent, according to published data. The findings offer a fresh snapshot of the side-effect profile that has shadowed this class of cancer immunotherapy since its emergence. CAR-T cell therapy works by engineering a patient’s own T-cells to recognise and attack cancer.
The process triggers a systemic inflammatory response known as cytokine release syndrome, or CRS, when activated T-cells release large amounts of cytokines into the bloodstream. In clinical trials, the record shows CRS occurs in 40 percent to 90 percent of patients, with severe—grade 3 or higher—cases in 10 percent to 30 percent.
Symptoms range from fever to hypotension and respiratory failure.
Standard treatment and regulatory history
The standard treatment for CRS is tocilizumab, sold under the brand name Actemra, an IL-6 receptor antagonist. The Food and Drug Administration approved the drug for this specific indication in August 2017. The approval gave oncologists a targeted tool to manage the inflammatory cascade that can accompany CAR-T infusions.
Another common side effect is immune effector cell-associated neurotoxicity syndrome, or ICANS, which affects 20 percent to 60 percent of patients. Symptoms include confusion, aphasia, and seizures.
In the CTX-112 trial, ICANS occurred in 12 percent of patients, with severe cases in 2 percent.
FDA safety actions
In November 2023, the FDA issued a safety alert about a rare risk of T-cell malignancies after CAR-T therapy. The alert was based on 19 reported cases among over 27,000 treated patients. Those cases included T-cell lymphoma and T-cell leukemia.
The FDA now requires a black box warning on all CAR-T products. The agency also mandates 15-year follow-up for patients who receive the therapy.
The long surveillance period reflects the agency’s concern about secondary cancers that may take years to develop. On the timeline, the CTX-112 trial’s lower rates of severe CRS and ICANS—8 percent and 2 percent, respectively—compared with historical averages suggest that next-generation CAR-T designs may be improving the safety profile. But the trial remains one data point among many.
What to watch
Researchers continue to refine CAR-T constructs to reduce toxicity while maintaining anti-tumor potency. The FDA’s black box warning and the 15-year follow-up requirement will generate long-term safety data that could reshape how these therapies are deployed. The June 2024 CTX-112 results add to the evidence base, but the full picture of risks and benefits remains under construction. Consult your doctor for medical advice.
